Drugs / zagociguat
zagociguat
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04972227 | Sep 2021 → Apr 2022 | schizophrenia | Tisento Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04240158 | Jan → May 2020 | — | Tisento Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT03856827 | Feb → Oct 2019 | — | Tisento Therapeutics | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06961344 | Aug 2025 → Jul 2028 expected | MELAS syndrome | Tisento Therapeutics | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06402123 | Sep 2024 → Jun 2026 | MELAS syndrome | Tisento Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT04798989 | Nov 2021 → Nov 2022 | Alzheimer disease | Tisento Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04475549 | Nov 2020 → Jan 2022 | MELAS syndrome | Tisento Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | zagociguat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06402123 ↗ |
| Known as | CY6463 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04798989 ↗ |
| Known as | IW-6463 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04240158 ↗ |
| Action | Activate | “As a soluble guanylate cyclase (sGC) stimulator, CY6463 can cross the blood-brain barrier and boosts the activity of the nitric oxide-soluble guanylate cyclase-cyclic guanosine...” NCT04798989 ↗ |
| Modality | Small molecule | — CHEMBL5314620 ↗ |
| Route | Oral | “administered orally” NCT03856827 ↗ |